Moreover, changing in MET expression explored in clinical settings revealed that it is a mediator of anti-cancer drugs resistance, like EGFR inhibitor resistance in non-small cell lung cancer (NSCLC) [13,14] and colorectal cancer (CRC) [15], and also that it correlates with worse prognosis and aggressiveness [16], such as in hepatocellular carcinoma [17], breast cancer [18], and CRC [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.